Clinical trials: Ovarian Neoplasm Epithelial
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Ovarian Cancer
Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study
The goal of this observational study is to evaluate whether polygenic risk score (PRS) assessment can help predict the onset of epithelial ovarian cancer in women aged over 18, comparing those with a histologically confirmed…
- Trial name
- PROVE (NCT06935344)
- Testing
- Polygenic Risk Score, Biopsy on normal contralateral ovary, Pharmacogenetic profiles
- Where
- Italy
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Advanced Solid Tumor, Gynecologic Cancer
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04691375
- Testing
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 86 people
- Sponsor
- Ikena Oncology
Brain Tumors, Gastric Cancer
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying two different vaccines to treat patients who have gastric, prostate, or ovarian…
- Conditions
- Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00023634
- Testing
- KLH, GMCSF
- Where
- 13 sites in United States
- Volunteers
- 14 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003998
- Testing
- carboplatin, docetaxel, paclitaxel
- Where
- United Kingdom
- Volunteers
- 1,050 people
- Sponsor
- University of Glasgow
Epithelial Ovarian Cancer
Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
This project is part of a large multicenter multidisciplinary program that will thoroughly explore the needs and difficulties of patients with BCR as well as those involved in their care.
- Trial name
- VIVROVAIRE 2 (NCT02323568)
- Testing
- Gynecological consultation
- Where
- 18 sites in France
- Volunteers
- 179 people
- Sponsor
- Centre Francois Baclesse
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Cervical Adenocarcinoma, Cervical Adenosarcoma
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma
- Trial name
- NCT02020707
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Platinum-resistant Ovarian Cancer
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including…
- Trial name
- NCT05551507
- Testing
- IN10018 in combination with PLD
- Where
- 7 sites in China
- Volunteers
- 150 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Ovarian Cancer
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
To evaluate the efficacy and safety of preoperative olaparib monotherapy and preoperative olaparib plus pembrolizumab combination therapy in patients with untreated stage III, IV high-grade serous or Grade 3 endometrioid ovarian…
- Trial name
- OLAPem (NCT04417192)
- Testing
- Olaparib, Pembrolizumab
- Where
- 3 sites in Japan
- Volunteers
- 30 people
- Sponsor
- National Cancer Center Hospital East
Epithelial Ovarian Cancer
Ovarian Tumor Biopsies to Study Response to Treatments
This is a research study to look at differences in tumor tissue from ovarian cancer patients that may help to determine response and resistance to treatments.
- Trial name
- NCT02952521
- Testing
- Blood Draw, Tumor Tissue Biopsy
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University Health Network, Toronto
Solid Tumor, Epithelial Ovarian Cancer
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
- Conditions
- Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- MUIR (NCT04516447)
- Testing
- Azenosertib, Carboplatin, Pegylated liposomal doxorubicin
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 172 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Epithelial Ovarian Cancer
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed…
- Trial name
- OVHM-01 (NCT00889733)
- Testing
- Intraperitoneal (IP) Cisplatin
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Ovarian Neoplasm, Fallopian Tube Neoplasms
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05257408
- Testing
- Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- Corcept Therapeutics
Adenocarcinoma, Colorectal Cancer
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
Background: Many cancers produce two proteins, carcinoembryonic antigen (CEA) and mucin-1 (MUC-1). The PANVAC-V (PANVAC vaccinia) priming vaccine and PANVAC-F (PANVAC fowlpox) boosting vaccine contain human genes that cause…
- Conditions
- Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT00088413
- Testing
- PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cavity Cancer
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00217568
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00373217
- Testing
- MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine, tetanus toxoid helper peptide, carboplatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Craig L Slingluff, Jr
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 450 people
- Sponsor
- DualityBio Inc.
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics